There are currently 17 active clinical trials seeking participants for Primary Sclerosing Cholangitis research studies. The states with the highest number of trials for Autism participants are California, Virginia, Florida and Texas.
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
Recruiting
PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The investigators aim to close this gap by conducting a pilot human study in patients with PSC, using statin therapy as a model
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/19/2024
Locations: Stanford University, Stanford, California
Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
Recruiting
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/14/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Primary Sclerosing Cholangitis, PSC, Cholangiocarcinoma
Biobank for Cholestatic Liver Diseases.
Recruiting
This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/14/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Recruiting
Background: Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the liver. It can result in bile duct infections, cirrhosis, cancer, and end stage liver disease. Researchers want to learn more about this disease. Objective: To understand the biological causes of primary sclerosing cholangitis. Eligibility: Adults age 18 and older who have primary sclerosing cholangitis. Design: Participants will be screened with a medical history, physical exam, a... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
03/12/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Primary Sclerosing Cholangitis
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
Gender:
All
Ages:
12 years and above
Trial Updated:
03/05/2024
Locations: Southern California Research Center, Coronado, California +62 locations
Conditions: Primary Sclerosing Cholangitis
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Recruiting
This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the stud... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/27/2024
Locations: Om Research LLC, Lancaster, California +61 locations
Conditions: Primary Sclerosing Cholangitis
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
Recruiting
The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD). This study will establish a shared clinical registry and a learning health network for the participating sites focusing on collecting and transmitting clinical measurement data, information about processes, and participation in an improvement collaborative. Pediatric Autoimmune Hepatitis (AIH) and Primary Scleros... Read More
Gender:
All
Ages:
All
Trial Updated:
01/17/2024
Locations: Stanford University, Palo Alto, California +5 locations
Conditions: Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Detoxification of the Liver In PSC (Dolphin)
Recruiting
This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with primary sclerosing cholangitis. Participation in this study will take 8 weeks long and the study is structured as a cross-over study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication. Participation may also involve receiving an IV dose of the medication. The study will require participa... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/12/2023
Locations: Brigham and Women's Hospital, Chestnut Hill, Massachusetts
Conditions: Primary Sclerosing Cholangitis
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
Recruiting
This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.
Gender:
All
Ages:
Between 15 years and 80 years
Trial Updated:
12/12/2023
Locations: Charu Madhwani Jain, Boston, Massachusetts
Conditions: Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis in Children
Recruiting
Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver. The purposes of this study are to: Collect medical and other data to learn more about PSC, how it progresses, and... Read More
Gender:
All
Ages:
Between 2 years and 25 years
Trial Updated:
10/13/2023
Locations: Children's Hospital of Los Angeles, Los Angeles, California +11 locations
Conditions: Primary Sclerosing Cholangitis, Liver Diseases, Cholangitis, Sclerosing
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Recruiting
Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC). Secondary objectives: To evaluate the change in Alkaline Phosphatase (ALP) from baseline to 6 months post-treatment following treatment with hymecromone plus standard of care compared with standard of care. To evaluate changes in biomarkers of PSC disease during hymecromone treatment, namely:... Read More
Gender:
All
Ages:
Between 14 years and 75 years
Trial Updated:
10/04/2023
Locations: Stanford Clinic, Redwood City, California +1 locations
Conditions: Primary Sclerosing Cholangitis
Vancomycin for Primary Sclerosing Cholangitis
Recruiting
To find out if vancomycin is a safe and effective therapy for primary sclerosing cholangitis. Funding Source - FDA OOPD
Gender:
All
Ages:
Between 18 years and 76 years
Trial Updated:
09/01/2023
Locations: Mayo Clinic Arizona, Phoenix, Arizona +3 locations
Conditions: Primary Sclerosing Cholangitis